Navigation Links
Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
Date:8/16/2011

TARRYTOWN, N.Y., Aug. 16, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency has extended its target date to complete the priority review of the EYLEA Biologics License Application (BLA) for the treatment of neovascular age-related macular degeneration (wet AMD) to November 18, 2011, which is a three month extension from the original Prescription Drug User Fee Act (PDUFA) action date.  

The extension is a result of the agency classifying recent responses to questions regarding the chemistry, manufacturing, and controls (CMC) section of the BLA as a major amendment to the BLA.  The new action date will give the agency additional time to review the information submitted.

About EYLEAVascular Endothelial Growth Factor (VEGF) is a naturally occurring protein in the body.  Its normal role in a healthy organism is to trigger formation of new blood vessels (angiogenesis) supporting the growth of the body's tissues and organs.  However, in certain diseases, such as age-related macular degeneration, it is also associated with the growth of abnormal new blood vessels in the eye, which exhibit vascular permeability and lead to edema.  

EYLEA (aflibercept injection) for intravitreal use, also known as VEGF Trap-Eye, is a fully human fusion protein, consisting of portions of VEGF receptors 1 and 2, that binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF).  EYLEA is a specific and highly potent blocker of these growth factors.  EYLEA is specially purified and contains iso-osmotic buffer concentrations, allowing for injection into the eye.

Regeneron and Bayer HealthCare are collaborating on the global development of EYLEA for the treatment of neovascular age-related macular de
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
2. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
3. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
4. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
5. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
6. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
7. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
8. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
9. Anesiva Announces Second Quarter 2008 Financial Results and Update
10. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
11. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 - Elsevier, a world-leading provider of scientific, technical ... publication of a recent study in Reproductive ... showing that those with an abnormal chromosomal composition can ... developed to blastocysts, thereby classifying the risk of genetic ... same group has undertaken a retrospective study, using their ...
(Date:5/17/2013)... USA (PRWEB) May 17, 2013 •    First ... Globes Certified for sustainability ,     New facility will ... , Syngenta unveiled its new ... at the company’s RTP Innovation Center. The first of ... researchers to simulate any agricultural climate and precisely measure ...
(Date:5/17/2013)... May 17, 2013  Cellular Biomedicine Group (OTCQB: ... enrollment of the total projected enrollment required for ... and preliminary efficacy of the medical technology haMPC ... Osteoarthritis (KOA). To date the trial has had ... The Phase I open label clinical research trial ...
(Date:5/17/2013)... SAN JOSE, Calif. , May 17, 2013 ... an agreement has been reached with ... entire portfolio of anti-infective human monoclonal antibody (mAb) ... six anti-infective human mAb products for treatment of ... strains of Staphylococcus aureus , Pseudomonas ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... columns back I mentioned my first law of softwareany mildly ... it is an operating system. Youve seen it. The e-mail ... then helper applications in version three and so on. The ... the poster child for this kind of behavior is the ...
... season, and you've been poked and prodded by television ads, ... Kerry drank a beer at your neighborhood bar and George ... Cheney was spotted more in Wisconsin in 2004 than he ... John Edwards has been in the state so often he's ...
... Norlight Telecommunications , a Brookfield, Wisconsin, telecommunications ... service for small and medium-sized businesses in Wisconsin and ... offer the service to businesses in Minnesota, Michigan, and ... , , IPLive will integrate voice, data and ...
Cached Biology Technology:The first law of software 2The first law of software 3Twenty ways you can tell this campaign has finally pushed you over the edge 2
(Date:5/17/2013)... Sustainable Global Logistics Operations) is aiming to cut CO2 ... intermodal loading systems and the boosting of intelligent systems ... with experience in the logistics sector and in supply ... a duration of three and a half years. , ... components and ontologies shared by the users, objects and ...
(Date:5/17/2013)... Bethesda, MD The Federation of American Societies for ... of National Institutes of Health (NIH) funding trends highlighting ... to support critical research. The FASEB analysis follows a ... Francis Collins, MD, PhD, who testified that the $1.6 ... to sequestration is "having a substantial impact on the ...
(Date:5/16/2013)... 2013) Illustrating a commitment to the support ... Association (AGA) Research Foundation has announced the inaugural ... Award recipients. Supported by the National Institute of ... new award helps underrepresented minority students to further ... research. , "By establishing this new award, AGA ...
Breaking Biology News(10 mins):New logistics services that will cut energy consumption and CO2 emissions 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
... New Orleans, LA Research conducted by Dr. Jayne S. ... Center New Orleans, and colleagues has found that a defect ... cornea also contributes to the progression of invasive bladder cancer. ... the peer-reviewed journal, DNA and Cell Biology . It ...
... November issue of The American Naturalist : ... are sexy How global warming could cause animals to shrink How ... egg could lead to permanent problems For the complete ... . The singer not the song: Why some birds ...
... - An international team of scientists, including biologists from the ... for the first time the mechanism responsible for cell polyploidy, ... sets of chromosomes. When it comes to human chromosomes ... pairs. Bundled within the nucleus of our cells are 46 ...
Cached Biology News:Mutation in gene associated with rare eye disease also contributes to bladder cancer growth 2Why some birds think simple songs are sexy 2Why some birds think simple songs are sexy 3Why some birds think simple songs are sexy 4Growing without cell division 2
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
Rabbit polyclonal to SpUlp2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SNNERQSLSSGSND, corresponding to amino acids 622-635 of Schizosaccharomyces pombe SpUlp2...
STX18 Immunogen: STX18 (NP_058626, 101 a.a. ~ 200 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Request Info...
Biology Products: